

Veronica Balatti

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/11423674/publications.pdf>

Version: 2024-02-01

33
papers

2,141
citations

304368

22
h-index

414034

32
g-index

34
all docs

34
docs citations

34
times ranked

3552
citing authors

#	ARTICLE	IF	CITATIONS
1	A large fraction of trisomy 12, 17p ⁺ , and 11q ⁺ CLL cases carry unidentified microdeletions of <i>miR-15a/16-1</i> . Proceedings of the National Academy of Sciences of the United States of America, 2022, 119, .	3.3	3
2	Small Non-Coding RNAs in Leukemia. Cancers, 2022, 14, 509.	1.7	7
3	MicroRNA dysregulation and multi-targeted therapy for cancer treatment. Advances in Biological Regulation, 2020, 75, 100669.	1.4	20
4	Identification of tRNA-derived small RNA (tsRNA) responsive to the tumor suppressor, RUNX1, in breast cancer. Journal of Cellular Physiology, 2020, 235, 5318-5327.	2.0	48
5	Role of Non-Coding RNAs in the Development of Targeted Therapy and Immunotherapy Approaches for Chronic Lymphocytic Leukemia. Journal of Clinical Medicine, 2020, 9, 593.	1.0	13
6	Dysregulation of different classes of tRNA fragments in chronic lymphocytic leukemia. Proceedings of the National Academy of Sciences of the United States of America, 2019, 116, 24252-24258.	3.3	45
7	HNRNPL Restrains miR-155 Targeting of BUB1 to Stabilize Aberrant Karyotypes of Transformed Cells in Chronic Lymphocytic Leukemia. Cancers, 2019, 11, 575.	1.7	11
8	Genetic dynamics in untreated CLL patients with either stable or progressive disease: a longitudinal study. Journal of Hematology and Oncology, 2019, 12, 114.	6.9	5
9	Identification of tRNA-derived ncRNAs in TCGA and NCI-60 panel cell lines and development of the public database tRFexplorer. Database: the Journal of Biological Databases and Curation, 2019, 2019, .	1.4	36
10	MicroRNA Profiling of Salivary Duct Carcinoma Versus Her2/Neu Overexpressing Breast Carcinoma Identify miR-10a as a Putative Breast Related Oncogene. Head and Neck Pathology, 2019, 13, 344-354.	1.3	12
11	BCL2 and miR-15/16: from gene discovery to treatment. Cell Death and Differentiation, 2018, 25, 21-26.	5.0	146
12	<i>MicroRNA</i> dysregulation to identify therapeutic target combinations for chronic lymphocytic leukemia. Proceedings of the National Academy of Sciences of the United States of America, 2017, 114, 10731-10736.	3.3	48
13	Role of the tRNA-Derived Small RNAs in Cancer: New Potential Biomarkers and Target for Therapy. Advances in Cancer Research, 2017, 135, 173-187.	1.9	60
14	tsRNA signatures in cancer. Proceedings of the National Academy of Sciences of the United States of America, 2017, 114, 8071-8076.	3.3	202
15	Novel Mechanisms of Regulation of miRNAs in CLL. Trends in Cancer, 2016, 2, 134-143.	3.8	30
16	Dysregulation of a family of short noncoding RNAs, tsRNAs, in human cancer. Proceedings of the National Academy of Sciences of the United States of America, 2016, 113, 5071-5076.	3.3	183
17	<i>TCL1</i> targeting <i>miR-3676</i> is codeleted with tumor protein p53 in chronic lymphocytic leukemia. Proceedings of the National Academy of Sciences of the United States of America, 2015, 112, 2169-2174.	3.3	63
18	Role of microRNA in chronic lymphocytic leukemia onset and progression. Journal of Hematology and Oncology, 2015, 8, 12.	6.9	72

#	ARTICLE	IF	CITATIONS
19	miR-15b/16-2 deletion promotes B-cell malignancies. Proceedings of the National Academy of Sciences of the United States of America, 2015, 112, 11636-11641.	3.3	98
20	Translocation t(2;11) in CLL cells results in CXCR4/MAML2 fusion oncogene. Blood, 2014, 124, 259-262.	0.6	11
21	Cross-talk between MET and EGFR in non-small cell lung cancer involves miR-27a and Sprouty2. Proceedings of the National Academy of Sciences of the United States of America, 2013, 110, 8573-8578.	3.3	105
22	B-cell malignancies in microRNA $\frac{1}{4}$ -miR-17 \hat{a} $\frac{1}{4}$ 92 transgenic mice. Proceedings of the National Academy of Sciences of the United States of America, 2013, 110, 18208-18213.	3.3	69
23	In vivo NCL targeting affects breast cancer aggressiveness through miRNA regulation. Journal of Experimental Medicine, 2013, 210, 951-968.	4.2	121
24	A Sleeping Beauty screen reveals NF- κ B activation in CLL mouse model. Blood, 2013, 121, 4355-4358.	0.6	31
25	miR Deregulation in CLL. Advances in Experimental Medicine and Biology, 2013, 792, 309-325.	0.8	23
26	In vivo NCL targeting affects breast cancer aggressiveness through miRNA regulation. Journal of Cell Biology, 2013, 201, i4-i4.	2.3	0
27	Tcl1 protein functions as an inhibitor of de novo DNA methylation in B-cell chronic lymphocytic leukemia (CLL). Proceedings of the National Academy of Sciences of the United States of America, 2012, 109, 2555-2560.	3.3	58
28	Novel Insights in Molecular Mechanisms of CLL. Current Pharmaceutical Design, 2012, 18, 3363-3372.	0.9	14
29	NOTCH1 mutations in CLL associated with trisomy 12. Blood, 2012, 119, 329-331.	0.6	190
30	MiR-181b: new perspective to evaluate disease progression in chronic lymphocytic leukemia. Oncotarget, 2012, 3, 195-202.	0.8	46
31	miR-181b is a biomarker of disease progression in chronic lymphocytic leukemia. Blood, 2011, 118, 3072-3079.	0.6	115
32	MicroRNAs Dysregulation in Human Malignant Pleural Mesothelioma. Journal of Thoracic Oncology, 2011, 6, 844-851.	0.5	77
33	Karyotype-specific microRNA signature in chronic lymphocytic leukemia. Blood, 2009, 114, 3872-3879.	0.6	179